BRPI0915064A2 - derivados de qunoxalinadiona - Google Patents
derivados de qunoxalinadionaInfo
- Publication number
- BRPI0915064A2 BRPI0915064A2 BRPI0915064A BRPI0915064A BRPI0915064A2 BR PI0915064 A2 BRPI0915064 A2 BR PI0915064A2 BR PI0915064 A BRPI0915064 A BR PI0915064A BR PI0915064 A BRPI0915064 A BR PI0915064A BR PI0915064 A2 BRPI0915064 A2 BR PI0915064A2
- Authority
- BR
- Brazil
- Prior art keywords
- qunoxalinadione
- derivatives
- qunoxalinadione derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290564.7 | 2008-06-16 | ||
| EP08290564 | 2008-06-16 | ||
| PCT/EP2009/003538 WO2009152909A1 (en) | 2008-06-16 | 2009-05-19 | Quinoxalinedione derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0915064A2 true BRPI0915064A2 (pt) | 2015-10-27 |
| BRPI0915064B1 BRPI0915064B1 (pt) | 2019-10-08 |
| BRPI0915064B8 BRPI0915064B8 (pt) | 2021-05-25 |
Family
ID=40823394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915064A BRPI0915064B8 (pt) | 2008-06-16 | 2009-05-19 | derivados de quinoxalinadiona, seus usos, e medicamentos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8329698B2 (pt) |
| EP (1) | EP2285786B1 (pt) |
| JP (1) | JP5596676B2 (pt) |
| KR (1) | KR101641391B1 (pt) |
| CN (1) | CN102066342B (pt) |
| AR (1) | AR072148A1 (pt) |
| AU (1) | AU2009259754B2 (pt) |
| BR (1) | BRPI0915064B8 (pt) |
| CA (1) | CA2728018C (pt) |
| CO (1) | CO6321252A2 (pt) |
| CY (1) | CY1114737T1 (pt) |
| DK (1) | DK2285786T3 (pt) |
| EA (1) | EA020236B1 (pt) |
| EC (1) | ECSP11010760A (pt) |
| ES (1) | ES2436195T3 (pt) |
| HR (1) | HRP20131069T1 (pt) |
| IL (1) | IL209421A (pt) |
| MX (1) | MX2010013577A (pt) |
| MY (1) | MY155695A (pt) |
| NZ (1) | NZ590503A (pt) |
| PL (1) | PL2285786T3 (pt) |
| PT (1) | PT2285786E (pt) |
| SI (1) | SI2285786T1 (pt) |
| WO (1) | WO2009152909A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| CN103435561B (zh) * | 2013-08-19 | 2016-08-10 | 上海交通大学 | 一种新型d-氨基酸氧化酶抑制剂及其制备和应用 |
| DK3424920T3 (da) | 2013-10-17 | 2020-06-08 | Vertex Pharma | Co-krystaller af (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinolin-4-carboxamid og deuterede derivater deraf som dna-pk-inhibitorer |
| JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法 |
| EP3941496A4 (en) * | 2019-03-18 | 2022-11-23 | University of Washington | METHODS OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS |
| CN110642798B (zh) * | 2019-11-10 | 2020-07-24 | 湖南科技学院 | 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| KR20230012597A (ko) | 2020-05-19 | 2023-01-26 | 칼리오페, 인크. | Ampk 활성화제 |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| EP4221700A1 (en) | 2020-09-30 | 2023-08-09 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| EP4249489A4 (en) * | 2020-11-26 | 2023-10-18 | Lg Chem, Ltd. | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3238252A1 (en) | 2021-11-19 | 2023-05-25 | Amit Choudhary | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| EP0963372A1 (en) | 1997-02-18 | 1999-12-15 | American Home Products Corporation | 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists |
| AU2002314101A1 (en) | 2001-05-25 | 2002-12-09 | Boehringer Ingelheim Pharma Gmbh &Co. Kg | Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| MXPA06007715A (es) | 2004-01-06 | 2007-01-26 | Johnson & Johnson | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad. |
| MY139645A (en) * | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
| EP2018167A4 (en) * | 2006-05-15 | 2010-07-14 | Irm Llc | COMPOSITIONS AND METHODS AS INHIBITORS OF FGF RECEPTOR KINASES |
| FR2903695B1 (fr) * | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2009
- 2009-05-19 HR HRP20131069AT patent/HRP20131069T1/hr unknown
- 2009-05-19 US US12/997,641 patent/US8329698B2/en not_active Expired - Fee Related
- 2009-05-19 ES ES09765489T patent/ES2436195T3/es active Active
- 2009-05-19 DK DK09765489.1T patent/DK2285786T3/da active
- 2009-05-19 JP JP2011513895A patent/JP5596676B2/ja not_active Expired - Fee Related
- 2009-05-19 EP EP09765489.1A patent/EP2285786B1/en active Active
- 2009-05-19 KR KR1020117000992A patent/KR101641391B1/ko not_active Expired - Fee Related
- 2009-05-19 CN CN2009801227397A patent/CN102066342B/zh not_active Expired - Fee Related
- 2009-05-19 PT PT97654891T patent/PT2285786E/pt unknown
- 2009-05-19 EA EA201100007A patent/EA020236B1/ru not_active IP Right Cessation
- 2009-05-19 PL PL09765489T patent/PL2285786T3/pl unknown
- 2009-05-19 AU AU2009259754A patent/AU2009259754B2/en not_active Ceased
- 2009-05-19 BR BRPI0915064A patent/BRPI0915064B8/pt not_active IP Right Cessation
- 2009-05-19 NZ NZ590503A patent/NZ590503A/xx not_active IP Right Cessation
- 2009-05-19 WO PCT/EP2009/003538 patent/WO2009152909A1/en not_active Ceased
- 2009-05-19 CA CA2728018A patent/CA2728018C/en active Active
- 2009-05-19 MX MX2010013577A patent/MX2010013577A/es active IP Right Grant
- 2009-05-19 MY MYPI2010005917A patent/MY155695A/en unknown
- 2009-05-19 SI SI200930812T patent/SI2285786T1/sl unknown
- 2009-06-16 AR ARP090102166A patent/AR072148A1/es active IP Right Grant
-
2010
- 2010-11-18 IL IL209421A patent/IL209421A/en active IP Right Grant
- 2010-12-14 CO CO10156748A patent/CO6321252A2/es active IP Right Grant
-
2011
- 2011-01-14 EC EC2011010760A patent/ECSP11010760A/es unknown
-
2012
- 2012-08-24 US US13/593,722 patent/US8674097B2/en active Active
-
2013
- 2013-12-27 CY CY20131101166T patent/CY1114737T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| EP2376493A4 (en) | DIHYDROPYRIMIDOPYRIMIDINDERIVAT | |
| EP2380877A4 (en) | PYRIDINE-3-CARBONSÄUREAMIDDERIVAT | |
| BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
| BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
| BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
| BRPI0812155A2 (pt) | derivados de espiroindolinona | |
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| BRPI0817935A2 (pt) | Derivados de biarila | |
| BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
| DK2209786T3 (da) | Pyrimidinsubstituerede purinderivater | |
| DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
| BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
| BRPI0813836A2 (pt) | Derivados pirazólicos | |
| BRPI0812518A2 (pt) | Derivados de indazolamida | |
| EP2336132A4 (en) | MORPHOLINPURINDERIVAT | |
| BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| DK2275414T3 (da) | Cyclopentylacrylamidderivat | |
| DK2152370T3 (da) | Aryletherpyridazinonderivater | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2828 DE 18-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |